Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer

Abstract

Whole-body MRI is an effective method for evaluating the entire skeletal system in patients with metastatic disease. This study aimed to compare whole-body MRI and radionuclide bone scintigraph in the detection of skeletal metastases in patients with prostate cancer. Patients with prostate cancer at high risk of skeletal metastasis with (i) prostate-specific antigen of > or =50 ng/mL; (ii) composite Gleason score of > or =8 with prostate-specific antigen of >20 ng/mL; or (iii) node-positive disease were enrolled in this prospective study before systemic treatment was initiated. Whole-body MR images and bone scans of 39 patients were analysed. Seven patients had bone metastases on bone scans, while seven patients had skeletal metastases by whole-body MRI, with concordant findings only in four patients. Compared with the 'gold standard', derived from clinical and radiological follow-up, the sensitivity for both bone scans and MRI was 70%, and the specificity for both was 100%. Magnetic resonance imaging detected 26 individual lesions compared with 18 lesions on bone scans. Only eight lesions were positive on both. Bone scans detected more rib metastases, while MRI identified more metastatic lesions in the spine. Whole-body MRI and radionuclide bone scintigraphy have similar specificity and sensitivity and may be used as complementary investigations to detect skeletal metastases from prostate cancer.

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CT

“…Extraprostatic nodal involvement per patient was confi rmed by means of patho logic proof alone. Skeletal involvement was confi rmed with either biopsy or a typical appearance on MR images ( 25 ). The absence of extraprostatic disease was confi rmed with either a substantial reduction in PSA level after prostatic bed therapy without a substantial increase in 6 months as mentioned earlier and/or stable appearance on CT or MR images for more than 1 year without evidence of nodal or bone involvement.…”

Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-β

“…In cases in which immune therapies for cancer are indicated, the effects of MSCs will require serious consideration. The findings of this study might not be limited to breast cancer because these phenomena may include other cancers that metastasize to the BM, including prostate cancer and melanoma (51).…”

Diagnostic value of whole‐body magnetic resonance imaging for bone metastases: a systematic review and meta‐analysis

“…The other studies conducted WB-MRI without DWI; seven studies used both histopathology and clinical follow-up as reference standards (20,22,23,25,27,(29)(30); three studies used only clinical follow-up evidence as the reference standard (24,27,28); one study used only clinical follow-up evidence as the reference standard (21). Of all 11 studies, five studies (23,(26)(27)(28)30) enrolled patients prospectively. Six studies (20-22,24,25,29) were retrospective database reviews.…”

“…Five studies enrolled patients in a consecutive manner (20,23,27,29,30). For total scan time including patient positioning, six studies (20)(21)(22)(23)(24)28) were within 55 minutes, one study (27) was 75.8 minutes, and the others were not documented.…”